<SEC-DOCUMENT>0000200406-13-000117.txt : 20131119
<SEC-HEADER>0000200406-13-000117.hdr.sgml : 20131119
<ACCEPTANCE-DATETIME>20131119172516
ACCESSION NUMBER:		0000200406-13-000117
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131119
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131119
DATE AS OF CHANGE:		20131119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1212

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		131230933

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201311198-kasrhip.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 1119 8-K ASR Hip</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sCF1E2D1AE5FE9740B2C2E0F7DF520596"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):   November 19, 2013</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="jjlogo.gif" style="height:62px;width:241px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="31%"></td><td width="38%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;&#160;08933</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)  &#160;(Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  732-524-0400</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sCF1E2D1AE5FE9740B2C2E0F7DF520596"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01&#160;&#160;&#160;&#160;Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant's subsidiary, DePuy Orthopaedics, Inc., and the Court-appointed committee of lawyers representing ASR&#8482; Hip System plaintiffs today announced a settlement agreement to compensate eligible ASR patients in the United States who had surgery to replace their ASR hip, known as revision surgery, as of August 31, 2013.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. settlement is valued at approximately $2.5 billion, based on an estimate of 8,000 patients participating in the program.   </font><font style="font-family:inherit;font-size:10pt;">The amount of the settlement program has been included as part of previously accrued amounts, and no additional charge to the company&#8217;s earnings is being recorded in connection with this settlement. Any remaining related established product liability reserve is based on currently available information and changes to the reserve may be required in the future as additional information becomes available. The majority of the payments related to this settlement are projected to occur during 2014 from currently available cash.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated November 19, 2013 is attached as Exhibit 99.1 to this Report.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release dated November 19, 2013.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="33%"></td><td width="24%"></td><td width="5%"></td><td width="24%"></td><td width="14%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 19, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Douglas K. Chia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Douglas K. Chia</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a201311198-kasrhipsettleme.htm
<DESCRIPTION>PRESS RELEASE - ASR HIP SETTLEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 1119 8-K ASR Hip Settlement Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s33073fa6fd0d49b1a89defa95618bf9c"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Contacts:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lorie Gawreluk</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mindy Tinsley</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-1413</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-574-372-7136</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lgawrel1@its.jnj.com</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mtinsley@its.jnj.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investor Contacts:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Louise Mehrotra</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lesley Fishman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-6491</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-3922</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LMehrot@its.jnj.com</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LFishma@its.jnj.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:180%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DePuy Announces U.S. Settlement Agreement to Compensate ASR&#8482; Hip System Patients </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Who Had Surgery to Replace Their ASR Hip</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WARSAW, IN, November 19, 2013 - DePuy Orthopaedics, Inc. (DePuy) and the Court-appointed committee of lawyers representing ASR&#8482; Hip System plaintiffs today announced a settlement agreement to compensate eligible ASR patients in the United States who had surgery to replace their ASR hip, known as revision surgery, as of August 31, 2013.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;We are committed to the well-being of ASR patients, as demonstrated by the voluntary recall and the program providing support for recall-related care,&#8221; said Andrew Ekdahl, Worldwide President, DePuy Synthes Joint Reconstruction. &#8220;The U.S. settlement program provides compensation for eligible patients without the delay and uncertainty of protracted litigation. DePuy remains committed to our purpose of advancing innovative treatment options to serve those who need joint replacement surgery.&#8221;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. settlement is valued at approximately $2.5 billion, based on an estimate of 8,000 patients participating in the program. The amount of the settlement program has been included as part of previously accrued amounts, and no additional charge to the company&#8217;s earnings is being recorded in connection with this settlement. Any remaining related established product liability reserve is based on currently available information and changes to the reserve may be required in the future as additional information becomes available. The majority of the payments related to this settlement are projected to occur during 2014 from currently available cash.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Settlement Program</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">For U.S. ASR Patients Who Had Surgery to Remove Their ASR Hip As of August 31, 2013</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. settlement program is available for U.S. ASR patients who had revision surgery for reasons related to the recall as of August 31, 2013. Patients eligible for this program can speak with their lawyer, if they have one, or contact the U.S. settlement program claims processor at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.USASRHipSettlement.com</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">or (877) 391-3169. ASR patients do not need a lawyer to participate in the program.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">For U.S. ASR Patients Who Have Surgery to Remove Their ASR Hip After August 31, 2013</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For U.S. patients who have revision surgery after August 31, 2013, the existing Broadspire program providing support for recall-related care is available. U.S. patients are encouraged to call 1-888-627-2677 for more information.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For more information about the U.S. settlement program, please visit </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.ASRHipInfo.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Status of Litigation</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Judge David Katz of the U.S. District Court of the Northern District of Ohio is presiding over the federal multidistrict litigation. The consolidated state litigations are presided over by: Judge Brian Martinotti of the Superior Court of New Jersey, Bergen County; Judge Deborah Mary Dooling of the Circuit Court of Cook County, Illinois; and Judge Richard Kramer of the San Francisco County Superior Court, California. The settlement agreement was presented to these judges and Maryland State Court Judge, the Honorable Crystal Dixon Mittelstaedt, at a court hearing today.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The settlement agreement will help bring to a close significant ASR litigation activity in the U.S.  However, some lawsuits in the </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s33073fa6fd0d49b1a89defa95618bf9c"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. will remain. DePuy will continue to defend against remaining claims and believes its actions related to the ASR Hip System have been appropriate and responsible.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recall Background</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2010, DePuy issued a voluntary recall of the ASR Hip System after receiving new information from the UK National Joint Registry as part of the company&#8217;s ongoing surveillance of post-market data concerning the ASR Hip System, which showed a revision rate that was not in line with data previously reported in that registry. The product continues to perform well in some patients. Since the recall</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decision was made, DePuy has worked to provide patients and surgeons with the information and support they need, including the global program providing support for recall-related care, which has thus far resulted in thousands of payments to patients.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DePuy Orthopaedics, Inc. is part of DePuy Synthes Companies of Johnson &amp; Johnson.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(This release contains &#8220;forward-looking statements&#8221; as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Orthopaedics, Inc. and Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &amp; Johnson&#8217;s Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;color:#1f487c;">, </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.investor.jnj.com</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">or on request from Johnson &amp; Johnson. Neither DePuy Orthopaedics, Inc. nor Johnson &amp; Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Visit </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.ASRHipInfo.com</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">for more information.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:304px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">###</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>jjlogo.gif
<TEXT>
begin 644 jjlogo.gif
M1TE&.#EAM0`O`/<``)H<*8\S/HT\.YDC*9@J-9@X)I8U.ZD:'K<-#K@,&;@5
M&ZL:)ZD<-+H:)[@9,JDB'ZDE**8H-J,T/*<Z-:\R-:XT/*X\,:L\.;0D([0B
M+;,K*KDC)+PC+;PN++<G-K<S.I@Y2*4L0:@X1[HM1;@W1KPX5;-$-H]#38]/
M4)5"0))#2)E`1IY!5)153)=26J9%2*E+4Z=26K=#2+=&5;%23K=46*148;M+
M8;E99ZIE9ZQP<+=D;+YB:[]K:+IR:+1R<\H*&LH5&M$.%M0/&MH(%=T.'=$6
M#]45&\H*(L,2),83*\0;),(;+,L3(\H3+,H:(\H;*\D;,]@))M4)-M87)M,8
M-L,B*L(I+,PC(\HC*\4G-\DR)\DS.],C*M<E-],R-^42&>85)N85-_,<,>,C
M+>8I.NHQ+O$A+_\[/,4;0\8I1<<V1L([5-@G1-DM4-HY1]8Q4-,_5=P^5^,J
M1.@W2.`\5_\S3/<Y5\%$2\=+4\%,6\M!4,Q&6LI,5,Q)6LE56]E$2-A+5]U<
M7<I)8<979-A(8M5:9]%<=]M4=-M><-!E7<IG:,MG=L-T<\)U?,%\?,MQ<,]R
M?,]Z=\A\?M9E:-9H==9U>.9`0.1%6>I36OQ#2?5,7_A/5N=9:>-><O)+:?U7
M:?Y7<^1I:.=H=^9S<.1S>^%_?/)B;/IH=O!Q:_]S=?YT?+1]@,MX@\-]E=5I
M@-MWA.%OB.=VA?UD@/UM@O]OCOUWAOU\D\&`?J^2CLB'A\R4E\N;F=:"B-N,
ME-J7F-JCFM6DIM2PLN>&B>N'E.23AN>6F/B(B_V(EOV2BON6F.6;I?J)H?V9
MI?^=LNJADOJKGNFEI^:JMNBTJOBFJ?ZHM/RTK/ZVN?^LQ/VXQ?^\TNK!N_[#
MNO;&Q/_#P__#RO_*QO[*R__)U?_0Q__4S?[8V?_*X?_;Y?_>\/_CV__RWNCN
M[.SWZ^O\]_/K[/_CY/_DZ_[KY/[KZ__D\__E^O[L\__L^OWTZ_3V]/3U^O3]
M]/3^_?[S\_[T^_W[]/[^_BP`````M0`O`$<(_P#_"1Q(\-^^@P43*D1H\.`^
M@0P52IQ(L:+%BA$;0GQXL:/'CP7Q"?3WCV1)C"7]J03)LN7$?OU.CA08$Z)"
ME?[N<:SILB?(?N$\.#`'[UH60/(6"N27$QZ)!K:0Z:GWCY]`=@=KFBRI[U_,
MF/O:\:QJD*!*JPV[BOR7;VF[@C'C67(PRQZ].U&HW;NWE>Q`?^F>9:$B3L2U
MF.W:<91)L"M!M&];CI6XN.2]N;3DE0,2ALNU>,F.'"DG4%ZZ`M/NO<O0!%6$
M;.^>@A)G@%LZ3E3HH.KU;I4"#N*0$4IG38H86^?>R:B"R9Z]?_>0K;G'#YL#
M)[8BB`/W((LM>?SD\?^(\ND;+"U>UI0KETU*FW/U.CW!0$D>O"Y!CJ7+J:X8
MC7?Q'$/%&*@P4@\U01#6B@[Q7'-`%JA\$`XX&"R!BC@@1)..)D<T`-\U3CCA
M#4GVG"/"+_*\T\<1:&!R"SR5!+%%//S4N%!E_O`32R7WQ),-`=)095)E/A5I
MI%<8AG./>#/,4Q-:1T8I957U,#7EE5+6R%=?6'8)4D9>AAFE0QN):29E'*E4
M3R\&7"-.!.$L51"13FEQ#@B^5'EFD:J)4,DYK3@"3U(V#:15=!XHTPP(>NY9
M9'P-+&*?+**5PX\]VO#AP2+7>("*!\W,,T\U40!Q3#SQ=-*`![`(!,\Q"EC_
M@4.5U3@0!03R^"./.`#,4,Y>U9``A0+0^&!"*A^(D\T,'BQ``3?\S*-&%5HT
M0U5*CNV58S8>/'"-/.=0084I\=@S#S(1&"".''5T(L,Y\)CSB115O'-/-FH$
M<<4[_=23#1RW7K.D'PTTH$Q2\BP2P37JW'-.(<,J`@X$J%B@3#FRC."`%8+<
M4P\S:52Q!CR%_I503CG6,\@GMC10B9/]R!..#!FL44HY7_7S`PPX>[7+"\I<
MRT\U*4QC53_?R*"'."6]$P,(O3#%3D[#D!#!#,90)U`Y*.0`#TSW_'+U.57A
M!-X]P`2#5HW6<%%-!A"(\U4YQT10`2'4H.4O"]58_YG.'S*$8Q4_Y\3`"#HP
MR?/("\U\/<\R(.``SUGW@$-(!'Z2HPX[7BTC0C9,^7,.#"+XPI1C%?FS#`&_
MIJ/N9(Z>Z4]LF=T#BR5\C>0/ZK'W[OOO)P,O_/#$HU2\F&$1>1&9QW?$D?()
M*<]\\Q8YI!(\XO!P@C!04J1K-3M$8R/U-U;%3SW+/#W/13F50PPC[WA%_D#0
M\R..`VNHHTX@6A!*_V(P.9\C/%4.`D0C=V!J7HX\X8%KI,,9#CC@[BA3$G%$
MH0KD,,8+_#<_W0VD'J6`P"+@48]A4"$+\1-(/7*RE[TL!1X4:``=""$/>6AK
M(-'*U4!0M15^W#!'50'/.__``Z5ZS*.(5>+'DQCCCX><8P`9`!T\&K"$K%GE
M+#;4&E/B@0SCD$`OJ@'/0-Y1HZ.QT'_]@`<_PE(5Y]3#B/78DA++2!(EOE$C
M%N%',Z)`@G/<`T%':`8U"("*(E!!'OW(!B,T`($:4$,<6F@`,LHA`V5X00J@
MF$<]:G`,301A#>=`AB=0`04(G$,>G8J"%.[@@5*<8Q1,6$4][&$,&;Q!"]Z0
M!P0Y\,@1D$J2H?-'/08%CV8,`!;O>,<%,*",\ZTA"&\0QR`*,8<$4.,=YX"%
M#"Y`@&-<0T!->$<T<-",(P0A'4/S90.TH`QQ5(`:5J#"*H98B#(480B@(($X
MM"'_!2C\2AR'B(,'+'&.<P#B"&8H1R5D08LP=(&,'6%A-B(PBF9(@0JC$"(7
M@.`%6V@#&9MZXSD\@`0FG,-<'VB"%V"0*WD(8@E1^(X\5I$`)>P!1=58`S.T
M4`D;4F,)5*C6-40!`67$XQ[7:``0M)".>Y#C`&&X@QJ88<-J,"($`/#`!_+0
MC&[<(QPU($$V[$`%")3#.;:(0A+>4(UF=,(#XG@C,:8@!EF0D!I'"(,#JI&3
M;$1!"6H`4#@R`(0YC$`<Y0":%@9`CAY]@0P-0$4VFF$%I/1C'GRXZ##D`4(@
MC"$4(G@'E[B$PWJT0A?IN`8$7D$/JQPD)TH42&2\TH^<_]#6'FUQ53]<6S8Q
MCD1K\CM)/^@Q%IB0I2M,42)8%K,5?\#$'"DHQSLN)SB$Q(PI8'D+"R<H/Y.@
MA2?M8"%!.+@3X\:DCJ49B#M@`CN*V$\$XMA+,TKPG`Y&21Z5,`1?W@&#O)V7
MM/9MB3_N-P4WA!;``6:)KCK1AB@P(&LD@5Z"C3?AWJVDPE*2,(:/=.&$Z(-W
M&_Y2B(FGX0`G<,1G@EZ)$WQB%!^)>2UV\?)6/)$8RY@@"61>>SO($.K4J!X<
MK(B/DX)@ZNTCMSXLXS^N95SEP?9L:YDP0QY2(V/,H!J54-M%]$@"600@&[NM
M\-3N48X81"(;(G#21IP\NQGPP?\0+K!*E"N<(W1=$QD,(%N'2Z;$I(+B'#7(
MDVMI##S"B6`&!7V!+K2VW)/%8PU1^$8STER6^2DO9H2(PBWBD0X.<.$>(UG,
M3J@4@PRLHAH2*,=6;%QH;SA`#35$15[XPCG8/02I54!".1HQB6L%6"4<J8<R
M(/"N>33C"5_0R=H&`FKHJ`8`6K#%&AHW1U`_!"87UI9(C*N/:R^E)CSA2\RN
M\EOO&NHQ\;@`!YIAKC8X02\=+NY>BI&$,@C'MUD9R='ZX0Z<R&DCZZ`)3283
M;IH0"L0F^R!1(<%965#A"4F!R>-:8(U%U*!O(LT`%1KPC7240Q("B-,^PE,*
M"02C-,C_$`$N",4/5FRC1SER7PU:,(X>]$!P_<CF#!S!67LLZP4].YD_WO*-
M#T#@&H1;PA.,H=QZE",'/_!&#'1A*7[``QEBD((L4D0-&5#"1D,3`0S(V(\R
M`_UHXK#!"O71+RROH!FPJ`$PFHI*'+S`&BJ91RM"T(Q&5X0?J&A`#6JHC"`<
MX5OBF$$3J'"-<HR@%IOP`#)NH(8D4,$6Q-&"N%!1CWZ(XP!DH$*3X#$#+U"!
M`[^2AR&TL-==$\(65"A#.:@Q`64`8@TBN`4RM,!,>!!C#E)P`C*NZ&]^4,,'
MX=`,`#!PC7J<`PI4$`4VS],`0YPC%&X`*24J00(M2&$.\2A'_Z;#@(!?U:,2
M59`"!XQJC#<@H374R48#G@`(XDC@%F2U!CGP@`I5:``/?N`,;R`$E[`>)9!^
M7N`DN14]9E$.0I$-\F`-05`$F+`PQP`&9!`__5(.)@`-\7`.&;`$JW`,E%`.
M'T`%J'`.&E0.FD`%@/`-8J4*#:`!ZT$(R-!%4H`<[_`"4&$/,%%,'K`DU>`!
M#=`,J$`+WX`!&W`,6Q(.E2`".=`+V;`&?W`.Z4`*#7`*LQ0(*L4%B2`.98`%
M1@5DZ3`,,E`.`7($9%`.*B`.S1`$02!=+U`-UX`!DH0*J^`-&Q`$J``/U"!6
M9Q`&56`.QE8%2<`7=G$.;&`,*8('1O^`!M4@`N5`"4>`!3128V9!9B.@'NE`
M!D6`"O;"#0F"#/`P#Q%8`$T%#QK7!'9U#A60!:`0",1P#^F0">+B`>60#K:0
M!0TP4=E`25Z`!(8P1)3`42=50Y1`"4*H>5JP6>4``4&`#.+@`O+@"PX`!]5P
M#K8`!1XP"HLP`U$0!<0`#[:P!!#05.>`"53P`4-$BR\`">GP#LH@!5*@3_70
M#%1`!,X``DT5#AR0!%IP#._PC$^`"J/`"/)0#%_0!0VD&5#0!,-`(_50#1'P
M#?;1!T-P!*`$(UV`!>G`"[G`/OH@A!'0!F4`!91`%4/3`%[@!%'@`3+P#3XX
M#P,0;>92#S/_4##?4"/R0`D+T$?A<0P.H`5ZP!?*L`:ND3<Y00FQH@4'($(T
M<@_>,`!<@`RY$@\0X`1SP`;HX$-+`@\%I0P\D"M\40YKT`1B4`40(),EX@=,
M\)+-(@MOU`_+D`9J(`XU0@T*@%'GD!/AP`#1)D01$`4-@`WS``\&@`P?,'A[
M<0T*L$X-D`$=@'27<@-1H`6J)@_#$(QJT`Q68A8W$7,S$!P>@`,^&!-+\@[P
M$#^+043?!0_/816<Y5M5,41Z`AY)Q&SW4(J=!Q:T%5NU%1Z^Y@]3$TQPL0BB
M4`Y6\PU4\1##-$16H1A>X4--I`_AH4.#(P_.<2C\`A/.X8-^L63SYH`.<52=
MYZ-&,O%&068RRN-\('!4$P4+1V00B3%;]+D5N?,5E28_UG-A/#$]E49P,=%M
M,U$F".<5]N`*NA`/\(`#$="7-39R.$&@<Y(2:[8/N5.@`G&@.%006[%C]),0
M\C`#S;`7U!`"I!%<-S81>C0#3`$/AM-Y,T%H+N8/UR`"?G0/E8`,(+JB?\$/
M;&`+>R$.K&,2>^:C"G$/T1`"V%`.C]`*Y]"C2*HK:X`)Y_`-ZI*A2&H1.8((
M:5`(VM`]6WH30\,`:H`,*Q1A8QJB%,%J:VH0^M`.'/JF=%JG=OIK$U%D&Q80
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
